Fabrice S. Schlatter

Fabrice S. Schlatter

Auto-generated profile, based on publicly available information

Fabrice S. Schlatter

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
RRRaphaël B. Di Roberto
Raphaël B. Di Roberto
FBFlorian Bieberich
Florian Bieberich
FSFabrice S. Schlatter
Fabrice S. Schlatter
DPDarya Palianina
Darya Palianina
SRSai T. Reddy
Sai T. Reddy
Chimeric antigen receptors (CARs) consist of an antigen-binding region fused to intracellular signaling domains, enabling customized T cell responses against targets. Despite their major role in T cell activation, effector function and persistence, only a small set of immune signaling domains have been explored. Here we present speedingCARs, an integrated method for engineering CAR T cells via signaling domain shuffling and pooled functional screening. Leveraging the inherent modularity of natural signaling domains, we generate a library of 180 unique CAR variants genomically integrated into primary human T cells by CRISPR-Cas9. In vitro tumor cell co-culture, followed by single-cell RNA sequencing (scRNA-seq) and single-cell CAR sequencing (scCAR-seq), enables high-throughput screening for identifying several variants with tumor killing properties and T cell phenotypes markedly different from standard CARs. Mapping of the CAR scRNA-seq data onto that of tumor infiltrating lymphocytes further helps guide the selection of variants. These results thus help expand the CAR signaling domain combination space, and supports speedingCARs as a tool for the engineering of CARs for potential therapeutic development.

1 December 2021 in Trends in Biotechnology
Verified
Journal Article
Closed access
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
RRRaphaël B. Di Roberto
Raphaël B. Di Roberto
FSFabrice S. Schlatter
Fabrice S. Schlatter
SRSai T. Reddy
Sai T. Reddy

1 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DPDarya Palianina
Darya Palianina
RRRaphaël B. Di Roberto
Raphaël B. Di Roberto
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
FSFabrice Schlatter
Fabrice Schlatter
SRSai T. Reddy
Sai T. Reddy
Nina KhannaNina Khanna
Nina Khanna
Adoptive cell therapy of donor-derived, antigen-specific T cells expressing native T cell receptors (TCRs) is a powerful strategy to fight viral infections in immunocompromised patients. Determining the fate of T cells following patient infusion hinges on the ability to track them in vivo . While this is possible by genetic labeling of parent cells, the applicability of this approach has been limited by the non-specificity of the edited T cells. Here, we devised a method for CRISPR-targeted genome integration of a barcoded gene into Epstein-Barr virus-antigen-stimulated T cells and demonstrated its use for exclusively identifying expanded virus-specific cell lineages. Our method facilitated the enrichment of antigen-specific T cells, which then mediated improved cytotoxicity against EBV-transformed target cells. Single-cell and deep sequencing for lineage tracing revealed the expansion profile of specific T cell clones and their corresponding gene expression signature. This method has the potential to enhance the traceability and the monitoring capabilities during immunotherapeutic T cell regimens.